<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(10)</volume><submitter>Liu H</submitter><journal>MedComm</journal><pagination>e70427</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12501409</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.</pubmed_title><pmcid>PMC12501409</pmcid><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors><pubmed_authors>Zeng H</pubmed_authors><pubmed_authors>Chuang Y</pubmed_authors><pubmed_authors>Sun G</pubmed_authors><pubmed_authors>Zhu Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.</name><description/><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-04T10:03:46.623Z</modification><creation>2026-06-02T03:07:52.057Z</creation></dates><accession>S-EPMC12501409</accession><cross_references><pubmed>41064127</pubmed><doi>10.1002/mco2.70427</doi></cross_references></HashMap>